 | Up a level |
Vollbrecht, C., Mairinger, F. D., Koitzsch, U., Peifer, M., Koenig, K., Heukamp, L., Crispatzu, G., Wilden, L., Kreuzer, K-A, Hallek, M., Odenthal, M., Herling, C. D. and Buettner, R. (2016). Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. Oncol. Res. Treat., 39. S. 159 - 160. BASEL: KARGER. ISSN 2296-5262
Vollbrecht, C., Mairinger, F. D., Schweighofer, C. D., Heukamp, L. C., Merkelbach-Bruse, S., Buettner, R. and Odenthal, M. (2014). Testing cancer related gene panels for high throughput parallel sequencing. Eur. J. Cancer, 50. S. S145 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Walter, R. F. H., Mairinger, F. D., Ting, S., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W. and Wohlschlaeger, J. (2015). MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br. J. Cancer, 112 (5). S. 883 - 891. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827
Walter, R. F. H., Mairinger, F. D., Ting, S., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W. and Wohlschlaeger, J. (2015). MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br. J. Cancer, 112 (5). S. 883 - 891. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827